Pharmaceutical Sciences, Discovery and Manufacturing Sciences, Janssen Research and Development, Beerse, Belgium.
Department of PK Sciences, Computational and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936.
J Pharm Sci. 2019 Jan;108(1):592-602. doi: 10.1016/j.xphs.2018.05.024. Epub 2018 Jun 12.
Food can alter the absorption of orally administered drugs. Biopharmaceutics physiologically based pharmacokinetic (PBPK) modeling offers the possibility to simulate a compound's pharmacokinetics under fasted or fed states. To advance the utility of PBPK modeling, with a view to regulatory impact, we have pooled our experience across 4 pharmaceutical companies to propose a general multistep PBPK workflow leveraging pre-existing clinical data for immediate-release formulations of Biopharmaceutics Classification System I and II compounds. With this strategy, we wish to promote pragmatic PBPK approaches for compounds where absorption is well understood, that is, compounds with moderate-to-high permeability that are not substrates for uptake transporters. Five case studies demonstrate how food effect can be well predicted using appropriately established and validated models. The case studies integrate solubility and dissolution data for initial model development and apply a "middle-out" validation with clinical data in one prandial state. Then, whenever possible, a validation against both fasted and fed state data is recommended before application of the models prospectively for to-be-marketed formulations. Thus, when combined with limited clinical data, PBPK models could be used to simulate outcomes for new doses, formulations, or active pharmaceutical ingredient forms, in lieu of a clinical food-effect study.
食物会改变经口给药药物的吸收。生理药代动力学(PBPK)模型为模拟空腹或进食状态下化合物的药代动力学提供了可能。为了推进 PBPK 模型的实用性,我们借鉴了 4 家制药公司的经验,提出了一种通用的多步骤 PBPK 工作流程,该流程利用现有临床数据对生物药剂分类系统 I 和 II 化合物的即释制剂进行建模。通过这种策略,我们希望为那些吸收机制已得到充分理解的药物(即具有中等至高渗透性且不是摄取转运体底物的药物)推广实用的 PBPK 方法。5 个案例研究展示了如何使用适当建立和验证的模型来很好地预测食物效应。这些案例研究将溶解度和溶解数据用于初始模型开发,并在一种进食状态下应用“中间向外”验证与临床数据。然后,只要有可能,建议在对新剂量、新配方或活性药物成分形式进行前瞻性应用之前,根据空腹和进食状态数据对模型进行验证,以替代临床食物效应研究。因此,当与有限的临床数据结合使用时,PBPK 模型可用于模拟新剂量、新配方或活性药物成分形式的结果,而无需进行临床食物效应研究。